

ImmunID announces the successful validation of its IFS4 Immune Forecast Station on a Roche Diagnostics France quantitative 480 PCR system.



ImmunID has established a technical collaboration for quantitative PCR with Roche Diagnostics France as part of its program for the industrialization and standardization of its 4th generation IFS stations. The aim of this collaboration was to qualify an IFS4 used in the Infectiology Center in Lyon by members of the PLATINE consortium. The project was successful in under 12 months thanks to the effective collaboration between the Applied Science department at Roche Diagnostics France and ImmunID.

"The results of this first technical collaboration between two members of Lyonbiopôle are very encouraging. They demonstrate that the LightCycler 480 is a flexible research instrument whose reliability makes a standardized technical approach possible for multiple parallel PCR reactions. This collaboration also validated a complete workflow integrating the LightCycler 480 and allowing the Molecular Biology analyses developed by ImmunID to reach a higher level of automation. This type of standardization is essential for the future implementation of ImmunID's tests on our Quantitative PCR machines for routine diagnosis in

specialized biology laboratories" indicates **Frank Willemsse, marketing director at Roche Diagnostics France.**

"We are delighted with the results of this collaboration between the French leader of *in vitro* diagnosis, Roche Diagnostics France, and a startup like ImmunID. They will help accelerate the time to market for innovative tests measuring the immune repertoire. By ranking patients according to their immune repertoire, these tests will help improve the success rate for clinical studies run by the pharmaceutical industry. Tests can be used from the phase of patient enrollment in the study, and throughout clinical follow-up. They will help improve assessment of the benefit/risk ratio for treatments, and will be instrumental in developing personalized medicine" indicates **Nicolas Pasqual, President of ImmunID.**

"The qualification of the IFS4 platform is the fruit of an active collaboration between Roche Diagnostics France and ImmunID at Lyonbiopôle's Infectiology Center. This success allows us to confidently offer immune repertoire analysis for patients enrolled in the clinical trials in which our company participates" adds **Jean-François Mouret, CTO at ImmunID.**

"The favorable results recently obtained by ImmunID Technologies as part of their technical collaboration with Roche Diagnostics France once again illustrate how the world-class competitiveness cluster, Lyonbiopôle, contributes to catalyzing innovation. We are very pleased to contribute to scientific animation and partnerships between multinationals and SMBs. This provided ImmunID with access to the Infectious Diseases Center at Lyonbiopôle as part of the "PLATINE" collaboration, and allowed qualification of their immune forecast station on a Roche Diagnostics system. Lyonbiopôle thus confirms its role in driving innovation and stimulating evolution in the fields of diagnosis, vaccines and biotherapies" concludes **Yves Laurent, General Manager at Lyonbiopôle.**

About the IFS4

Validation of the IFS4 platform required close collaboration between the participating teams in Lyon and Grenoble. The reproducibility and repeatability of immune repertoire analyses were analyzed. The IFS4 Immune Forecast station was qualified using ImmunTraCkeR® TRB tests and Constel'ID software. The station now allows industrial-scale study of the V(D)J immune repertoire for the human TRB chain. Validation of the human Immun'Ig® tests on the IFS4 platform is ongoing, and will allow complete analysis of the T and B cell repertoires in the near future.

About ImmunID: Located in Grenoble and Lyon, ImmunID is leader in the field of analysis of immune repertoire combinatorial diversity. Thanks to the original concept of "immune forecast", ImmunID offers diagnostic and innovative immunomonitoring solutions to characterize immune system dysfunctions, or to analyze the impact of immunotherapies on the immune repertoire. In the Biotech & Pharma sector, the ImmunTraCkeR® and Immun'Ig® solutions are used from the discovery stage through to clinical validation to measure the safety and efficacy of active molecules, including monoclonal antibodies (e.g. anti-CD20), interleukins (IL-2, IL-7 etc.), and vaccines (prophylactic and therapeutic).

About Roche Diagnostics France: Roche Diagnostics France is the French branch of the Roche group (Basel, Switzerland), responsible for diagnostic activities. Their headquarters are located in Meylan, near Grenoble. In 2010, Roche Diagnostics France had 598 employees and a turnover of 377.8 million euro. As the French leader of *in vitro* diagnostics, Roche Diagnostics France commercializes and distributes a full range of innovative products and services for medical biology (chemistry, immunology, molecular biology, delocalized biology), and research (cellular analysis, microarrays, genomics, high throughput sequencing), histopathology, and diabetology. For further information, see: www.rochediagnostics.fr

About Lyonbiopole: In 2005 Lyonbiopole was accredited as a world-class competitiveness cluster, it is located in the Rhône Alpes region, along the Lyon/Grenoble axis. Lyonbiopôle is a center of excellence in diagnostics and vaccines. Its objectives include improving the understanding of human and animal infectious diseases as well as cancer, with activities ranging from diagnosis and prevention through to treatment, while integrating novel routes of administration. This global approach aims to develop an inclusive "health shield" ranging from pathogen identification to protection of the populations at risk. Designed as a tool to interface and facilitate public/private partnerships, Lyonbiopôle styles itself as a catalyst for innovation, to reinforce the competitiveness of industries and the attractiveness of the region.

Link to the article presenting the launch of the project: <http://www.immunid-blog.com/article-immunid-et-roche-diagnostics-france-mettent-en-place-une-collaboration-technique-visant-a-standardiser-l-immunomonitoring-en-biologie-moleculaire-46576562.html>